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Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of
genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly
effective anticancer strategy. Two HPV L1 virus-like particle vaccines have been developed, a quadrivalent HPV16/18/6/11 product
and a bivalent HPV16/18 product; both have been shown to be highly immunogenic with a good safety profile and 100% efficacy
against HPV16/18-related high-grade cervical intra-epithelial neoplasia (CIN2/3), implying that they will be effective at preventing
HPV16/18-related cervical cancer.
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Papillomaviruses are a large family of small, double-stranded DNA
viruses that cause benign epithelial proliferations or warts in the
natural infection. These viruses have two key characteristics; first
they are absolutely host-specific, thus rabbit viruses only infect
rabbits, dog viruses only infect dogs, human papillomaviruses
(HPVs) only infect humans, secondly they are tissue-specific, a
complete infectious cycle occurs only in a fully differentiating
keratinised squamous epithelium. The HPVs are a very large
family, classified by genotype (DNA sequence) not by serotype. To
date, at least 200 HPVs have been isolated from tissue biopsies and,
of these, approximately 100 have been fully sequenced. Despite
their very large numbers, HPVs can be classified into two large
groups: those that infect skin, or cutaneous surfaces, and those that
infect the internal wet-squamous mucosal surfaces. Within these
groups there are low-risk types, which generate benign lesions, in
other words, warts, and high-risk or oncogenic types, which are
associated with cancers and their precursor lesions.
This is particularly apparent in the genital tract, where
approximately 40 HPV types regularly or sporadically infect the
mucosal epithelial surfaces. Low-risk HPV types, HPV6 and 11
cause more than 90% of genital warts with minor types (HPV42,
-44) and some high-risk HPVs contributing to about 10%.
Oncogenic HPVs in the genital tract are dominated by HPV16
and HPV18 which, with their close relatives, 31, 33, 35, 52, 58, 39,
45, 59, 56, 66 and 51, are the cause of cervical cancer (Clifford et al,
2003). Thus in 99% or more of biopsies of invasive cervical cancer
worldwide, HPV DNA sequences can be detected (Walboomers
et al, 1999), and in the high-risk precursor lesions, cervical intra-
epithelial neoplasia (CIN2, -3) approximately 80% contain the
high-risk HPVs (Clifford et al, 2003). HPV16 dominates, with at
least 50% of cancers irrespective of geographical location,
containing HPV16, followed by HPV18, 7 to 20%. Human
papillomavirus infection is not only the cause of invasive cervical
cancer and hrDNA sequences are found in a proportion of anal,
vulvar, vaginal, penile and head and neck cancers (Table 1).
HPV16 is the dominant oncogenic type followed by HPV18 and
overall, the malignant burden attributable to HPV infection is
calculated to be 3.71% of all cancers (Parkin and Bray, 2006)
The natural history of cervical intraepithelial neoplasia CIN is,
in effect, the natural history of HPV infection in the cervix.
Transient genital HPV infections, both of high- and low-risk HPVs,
are very common in young sexually active women with the lifetime
risk for acquiring a genital HPV infection in the UK of the order
of 70 to 80%. Most of these infections are transient and resolve.
If lesions develop, they are low-grade CIN1 and represent the
infectious cycle of the virus and are, in fact, flat papillomas.
However, a fraction of infected women (approximately 10 to 15%)
develop persistent HPV infection, and fail to clear virally infected
cells possibly because of the failure to develop a strong cell-
mediated immune response to HPV early proteins. These
persistent infections with oncogenic HPVs are at risk for
progression to the high-grade precursor lesion CIN2/3 and
approximately 30 to 40% of CIN2/3 then progress on to invasive
carcinoma (Mun ˜oz et al, 2006).
HPV VACCINES
Prophylactic vaccines have been and continue to be the most
effective strategy for controlling viral infections and papilloma-
viruses should be no exception to this. The antibody response to
HPV in humans is a serum neutralising antibody response to the
major capsid protein L1. However, neutralising antibody titres are
very low; the assay systems for detection of neutralising antibody
are not particularly sensitive and not all infected individuals
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mately 50% of women infected with HPV16 sero-convert; 70%
sero-convert to HPV6. In men sero-conversion rates for HPV16 or
18 are not clearly known, but sero-conversion against HPV6 is
found only in about 40% of men (Carter et al, 1995). Although
neutralising antibody titres are low evidence from animal
infections, including some of the earliest published works from
Shope, the founding father of papillomavirus research (Shope,
1937), showed very clearly that neutralising antibody was
protective. Thus if rabbits were infected systemically with the
cotton tail rabbit papillomavirus (CRPV) by direct injection of
virus into the muscle, papillomas did not arise in the infected
animals but neutralising antibody was generated and the animals
were completely resistant to viral challenge by abrasion of the
epithelium. This and other data suggested very strongly that
generating neutralising antibody to virus capsid protein would be
an effective prophylactic vaccine strategy. Neutralising antibodies
are directed against the L1 capsid protein and the generation of
this antibody requires the tertiary or native structure of the
protein. As these viruses cannot be grown in bulk in tissue culture
and viral particles particularly of the oncogenic types are sparse in
lesions, the generation of native structure, or properly folded L1
protein, was challenging. The challenge was met by the demon-
stration that if the L1 gene was expressed via a eukaryotic vector,
such as yeast (Jansen et al, 1995) or baculovirus (Kirnbauer et al,
1992), the L1 protein was produced in large amounts and self-
assembled into a macromolecular structure, a virus-like particle
(VLP) an empty capsid that is geometrically and antigenically
almost identical to the native virion. These VLPs were shown to
generate neutralising antibody in the animal models and
immunised animals were protected against high-level virus
challenge (Jansen et al, 1995; Suzich et al, 1995; Kirnbauer et al,
1996).
Two HPV L1 VLP prophylactic vaccines have been developed,
these are Cervarixt, a bivalent HPV16/18 VLP vaccine from
GlaxoSmithKline Biologicals (Rixensart, Belgium), and Gardasilt
also know as Silgard, a quadrivalent HPV16/18/6/11 vaccine from
Merck Vaccines (Merk & Co Inc, Whitehouse Station, NJ, USA)
(Table 2). Although the numbers are small, in the according-to-
protocol (ATP)groups in the Phase II trial of Cervarix there was
100% efficacy against the development of HPV16/18-asscociated
high-grade CIN2/3 (Harper et al, 2004, 2006). In the Phase III trials
of the Gardasil, the vaccine was 100% effective at preventing
HPV16/18 high-grade CIN2/3 and was 100% effective at preventing
HPV6/11/16 or 18-related external genital disease, that is genital
warts, vulval intra-epithelial neoplasia (VIN) and vaginal intra-
epithelial neoplasia (VAIN) (http: www.cdc.gov/nip/acip/slides/
jun06/hpv-2-barr.pdf; Villa et al, 2006), and this vaccine is now
licensed in many countries including those of the European Union
and the USA.
The assumption is that the neutralising antibody to L1 generated
by VLP vaccines or, after exposure to virus in natural infections,
provides protection but what is the evidence to support this? The
most convincing evidence is from preclinical experiments in dogs
and rabbits, in which passive transfer of purified immunoglobulin-G
from hyper-immune donors immunised with CRPV L1 VLPs, or
dogs after spontaneous regression of canine oral papillomavirus
(COPV), completely protected the naı ¨ve rabbit or dog recipient
from challenge with high viral innocula (Breitburd et al., 1995;
Ghim et al, 2000). Only animals immunised with intact VLPs
generated neutralizing antibody and only purified IgG from these
animals protected the naı ¨ve recipients. However, the question does
Table 1 The burden of malignant disease attributable to HPV infection
Developed countries Developing countries
SITE Attrib to HPV (%) Total cancers Attrib to HPV % all cancer Total cancers Attrib to HPV % all cancer
HPV infection – attributable cancer in 2002 (developed and developing countries)
Cervix 100 83400 83400 1.7 409400 409400 7.0
Penis 40 5200 2100 0.0 21100 8400 0.1
Vulva, Vagina 40 18300 7300 0.1 21700 8700 0.1
Anus 90 14500 13100 0.3 15900 14300 0.2
Mouth 3 91200 2700 0.1 183100 5500 0.1
Oro Pharynx 12 24400 2900 0.1 27700 3300 0.1
All Sites 5016100 111500 2.2 5827500 449600 7.7
It is estimated that 70% of all cervix cancers irrespective of geographical region are owing to HPV16/18 (Parkin and Bray, 2006). The current prophylactic vaccines might be
expected therefore to reduce the incidence of cervical cancer over the next several decades in unscreened populations by up to 70% depending upon vaccine coverage. In well-
screened populations the first effects would be a reduction in low-grade cervical abnormalities and CIN 3. It is estimated that up to 30% of low grade disease and 50% of CIN
would be prevented in the vaccinated populations.
Table 2 HPV L1 VLP vaccine profiles
Gardasilt Cervarixt
L1 VLP Antigens HPV6 20mg HPV16 20mg
HPV 11 40mg HPV 18 20mg
HPV 16 40mg
HPV 18 20mg
Expression system Yeast (Saccharomyces cerevisiae) Baculovirus
Adjuvant Proprietary aluminum hydroxyphosphate Sulfate
(225mg)
ASO4 aluminum hydroxide (500mg) plus 50mg
3-deacylated monophosphoryl lipid A
Injection volume and immunisation schedule 0.5ml i.m. 0, 2 and 6 months 0.5ml i.m. 0, 1 and 6 months
Adolescent safety/immunogenicity bridging trials Females and males 9–15 years Females 10–14 years
Males 10–18 years (in progress)
Licensed License application made
i.m.¼intramuscular.
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exclusively intra-epithelial infections of the cervix and lower
genital tract mucosa and skin. A persuasive hypothesis has been
that virus entry requires microtrauma to the epithelial surface and
there is some recent evidence (J Roberts, personal communication)
in an experimental model of infection that this can occur on
infection with epithelial denudation but with the retention of a
basement membrane, a scenario that would likely result in serous
exudation and rapid access of serum IgGs to the virus particles.
Furthermore, the portio surface of the cervix and the upper vaginal
epithelium are bathed in cervical mucous, and the dominant
immunoglobulin in cervical mucous is IgG transudated across the
endo-cervical and squamo-columnar surfaces (Nardelli Haefliger
et al, 2003). So, there is clearly rapid and easy access of serum
antibody to the virus particles explaining the extraordinary
efficacy of the VLP vaccines.
These vaccines are clearly remarkably efficacious in the short
term but what is the duration of the protection induced by the
vaccines? Will we need frequent booster vaccines? There is very
encouraging data from both Phase II and Phase III trials showing
that serum antibody levels fall from the peak levels achieved after
the third immunisation to a lower concentration that persists at
the same level for at least 60-months post-vaccination (Harper
et al, 2006; Mao et al, 2006; Villa et al, 2006). The antibody
concentrations in the plateau period in vaccinees are still 10 to 20
times that of natural infection. This data, combined with the
evidence from large-scale population studies of naturally-infected
individuals in which it can be shown that the antibody levels
persist for at least 10 years after natural infection (af Geijersstam
et al, 1999), leads to optimism that these vaccines will induce very
long-lasting protection. The immune correlates of protection have
so far not been established because all individuals in the trials
appear to have sero-converted and there have been no evident
vaccine breakthroughs.
The humoral immunity induced appears to be predominantly
type-specific and this raises the question of whether there is any
cross-protection afforded by the vaccines as there is considerable
amino-acid sequence homology in L1 between closely related HPV
types (Chen et al, 2000). There is evidence from the Phase II trial of
Cervarix that HPV16/18 vaccinees are partially protected against
incident infection with HPV31 and HPV45 (Harper et al, 2006).
The possibility of cross-protection from the VLP vaccines is
strengthened by the evidence that cross-reactive antibodies against
HPV31/45/52 and 58 are generated after vaccination with Gardasil
(Smith JV, personal communication) and, importantly, cross-
neutralising antibodies to HPV45 and 31 are generated after
vaccination with this vaccine albeit at concentrations 1 to 2log
lower than the dominant type-specific neutralising antibodies. It
must be emphasised however that, at the present time, there is no
evidence for cross-protection against HPV45 or 31 induced CIN2/3
and if such cross-protection does occur, it is likely to be partial and
not complete. This does imply that second generation vaccines will
need to include other HPV types and a frequently asked question
is, will we need different ‘cocktails’ of HPV types for different
populations. This seems unlikely. HPV16 and HPV18 are the
dominant types worldwide consistently detected in 70% of all
cervix cancers. A further six types, HPV45/31/56/52/35 and 33,
consistently make up the remaining 20 to 30%, irrespective of the
geographic region and a polyvalent vaccine that contained these
eight types would effectively protect against more than 90% of all
cervix cancers (Clifford et al, 2006).
A question that is currently generating more heat than light is,
who and when to vaccinate? HPV L1 VLP vaccines are prophylactic
not therapeutic preventing, not treating infection, and the available
evidence is clear that immunisation with them will not be effective
in individuals with established HPV infections of the types
included in the current vaccines. Genital HPV infection is usually,
but not always, sexually transmitted and for effective population-
based programmes, immunisation should precede the sexual debut
and the target population for vaccination, should therefore be
eleven to 12-year-old pre-pubertal girls. Immunologically this is
the optimal time because the immune system ‘ages’ after puberty.
Immunogenicity bridging studies from the quadrivalent vaccine
looking at antibody concentrations achieved after immunisation in
9- to 15-year-old girls and boys have shown that antibody levels
after HPV VLP vaccination are higher in 9- to 10-year-old girls
than 13- to 15-year-old girls, and higher in 13- to 15-year-old girls
than 16 to 23-year-old women. The levels are higher in 9- to 15-
year-old boys than in 9- to 15-year-old girls, suggesting that male
immunisation will be effective (Block et al, 2006). Certainly if herd
immunity against HPV is to be achieved, and virus transmission
interrupted effectively, then boys, as well as girls, should be
immunised. However, all the efficacy trials have included women
only and there is no efficacy data in men available although trials
are ongoing. The arguments against vaccinating boys against the
oncogenic HPVs are based on health economic considerations
and cost effectiveness. In a heterosexual population, the spread of
HPV infection can be stopped entirely by complete protection of
one sex alone and dynamic simulation models of HPV transmis-
sion show that if high coverage of females can be achieved, there is
little to be gained in the additional reduction of cervical cancer by
vaccinating males.
What about older women? Will these vaccines have any efficacy
in women who are sexually active and who may have been exposed
to HPV? The Phase III trials have shown that vaccination of HPV16
DNA-negative women – 16- to 23-year olds – does protect against
the development of HPV16/18-related CIN2 or -3, implying that
women in this age group, who are HPV16/18 DNA-negative, can be
vaccinated with confidence, in that they will be protected against
the development of 16/18-related disease. However, it is highly
unlikely that there will be prescreening for HPV infection in any
group, and sexually active women who are immunised would
therefore have to continue in a cervical cancer screening
programme, if that is available. The future of screening is another
frequently raised topic, will these vaccines eliminate the need for
cervical cancer screening programmes? The answer is, absolutely
not in the short or medium term. It seems clear that if the current
HPV prophylactic vaccines are introduced for mass immunisation
in countries with effective cervical screening programmes, then the
latter will have to continue unless significant cross-protection is
induced by VLP immunisation to the extent that the protection
against cervix cancer afforded by the vaccines is significantly
greater than the prevention of cervical cancer achieved with the
best population-based screening programmes, such as those in the
UK. The cervical screening programme in England, at present,
covers 80 to 82% of women at risk, and prevents 90% of cervical
cancers in that group, with an overall protection from cervix
cancer of the order of 76%. To discontinue this cancer-screening
programme would require the vaccines to achieve at least 85 to
90% prevention of cervical cancer. Even if immunisation with the
current vaccines was introduced for the 11- to 12-year old cohort,
both immunised and non-immunised population cohorts would
have continued in a screening programme as the immunised group
would still be at risk from the oncogenic types not in the vaccine.
What can be predicted is, that if vaccination is introduced the
nature of screening will change both in terms of screening
methods, with the use of molecular markers and HPV testing
rather than cytology and microscopy, and the number of occasions
on which women are screened.
HUMAN PAPILLOMAVIRUS VACCINES IN THE
DEVELOPING WORLD
The results from the VLP vaccine trials are immensely encouraging
and exciting but the great burden of cervix cancer is in women in
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these women faces some major hurdles. Vaccines for these women
must be cheap and easily delivered. The VLP vaccines will at least
initially be expensive; thus the vaccine is not yet widely available
but where it has been licensed the current price is over $100 per
dose (with three doses required to achieve full protection)
although manufacturers have declared their willingness to tier
prices for countries of different economic settings. The price at
which the vaccine is available is almost certainly going to be a
major determinant of the cost and affordability of any vaccine
programme. Universal programmes for delivering health care to
preadolescents are rare in the developing world, so the costs of
establishing and maintaining a new system for HPV vaccination
are likely to be considerable. Furthermore, social and cultural
values in many countries will make vaccination of female
adolescents extremely difficult. Infant vaccination reaches more
than 70% of children in the world even in the poorest countries
and realistically if HPV vaccines are to be delivered in such
settings then it will be as infant vaccines. However, immunogeni-
city-bridging trials to support this have not been implemented.
An important issue is whether the L1 vaccines will both be, and
remain, efficacious in immunocompromised subjects particularly
those who are HIV infected. In developing countries, there is
limited access to effective antiretroviral therapy raising questions
of safety, immunogenicity and the induction of effective immune
memory in such individuals. Clinical trials in HIV-infected
individuals are underway but no data are available as yet, although
one might predict that limited protection will be achieved in
individuals with low T-cell counts.
CONCLUSIONS
The HPV L1 VLP vaccines are immensely important developments
in public health and the benefits that they promise are immense,
offering the opportunity to prevent, in the long term, 80% of
cervical cancers, 60% of vulval and 90% of anal cancers in women.
They will impact significantly in the short to medium term on the
incidence of high-grade CIN reducing the number of women who
have to undergo large loop excision of the transformation zone
(LLETZ) and economically, in the long term, they will reduce
health-care costs. But the overwhelming benefit is the major
improvement for human health and well-being of women every-
where.
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